Thomas H. Pedersen - CEO at NMD Pharma | The Org
Detailed Description | NMD-GPS
NMD Pharma Information | NMD Pharma Profile
NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670 | Lifecarenews
NMD Pharma - PIR International
UNIVERSITY OF COPENHAGEN Project title Novel Treatments of Neuromuscular Disease Mentor 1 Pontus Gourdon, MSc & PhD,
NMD Pharma ApS Annual Report for 1 January - 31 December 2017
Tagged with NMDPharma - EY Danmark
NMD Pharma A/S | LinkedIn
Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle Neuromuscular Transmission Disorders #BioEquity2016… "
NMD Pharma begins first clinical trial: "Our entire team can be enormously proud"
Argenx køber amerikansk guldkupon til middel, som NMD Pharma skal konkurrere mod
NMD Pharma
Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email
NMD Pharma
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
NMD Pharma
Management team — NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma
NMD PHARMA's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"
Novo Holdings · NMD Pharma
